A*STAR PATENTS

The invention is directed to a nanostructured composite material comprising a mixture of at least one metal particle such as iron and a carbon material from biomass such as D-glucose, D-glucosamine hydrochloride or a-cyclodextrin. The invention is also directed to a composition comprising the composite material comprising the composite material and an inorganic salt, and a method for synthesizing the composite material comprising immersing the carbon material into a solution of metal ions, drying the impregnated carbon particle and subjecting the impregnated carbon particle to a carbothermal reduction process. The nanostructured composite material is useful as an oxygen scavenging layer in a multi-layer film which comprises the oxygen scavenging layer and an oxygen barrier layer that retards the permeation of oxygen from an external environment.

The present invention generally relates to polypeptides, polynucleotides, expression vectors, infectious clones, virus particles and immunogenic compositions of recombinant alphaviruses which can be used as vaccines. The present disclosure also relates to methods for eliciting an immune response against alphavirus infection using the immunogenic composition comprising the alphavirus mutants described herein.

The is provided a compound of formula I or II or physiologically acceptable salts or solvates, or oxidised derivatives thereof: where R1 to R3, R13 and R14 are as defined herein. Also disclosed herein are methods of dyeing hair or (temporarily) tattooing the skin using the compounds of formula I or II (or physiologically acceptable salts or solvates, or oxidised derivatives thereof) in a suitable composition.

Disclosed herein is a core-shell composite material comprising: a core optionally comprising an active ingredient compound; a shell structure comprising at least two alternating layers; the alternating layers being a protein layer and a polyphenol layer; and optionally a polyelectrolyte layer interfacing said core and said shell structure, said polyelectrolyte layer being disposed adjacent to said protein layer or said polyphenol layer, wherein said shell structure is selected to be resistant to degradation under gastric conditions but is degradable by one or more intestinal enzymes. In a preferred embodiment the protein is bovine serum albumin (BSA) or pepsin, the polyphenol layer is tannin or tannic acid, and the shell structure is degradable by pepsin.

An antigen-binding protein, or an antigen-binding fragment thereof that binds to a Lewis X type glycan on SLAMF7, comprising (1) a heavy chain variable domain comprising a VHCDR1 having the amino acid sequence GYTFTSYWIH; a VHCDR2 having the amino acid sequence EINPSNGRTNFNEKFKN and a VHCDR3 having the amino acid sequence VDYDEAY; and (ii) a light chain variable domain comprising a VLCDR1 having the amino acid sequence RSSKSLLHSNGITYLY, a VLCDR2 having the amino acid sequence QMSNLAS, and a VLCDR3 having the amino acid sequence AQNLELWT is provided. Methods of using the antibody for detecting or treating cancer, and a kit comprising the antibody are also provided.

A method for IP traceback is provided comprising receiving a traceback request including the identity of a traceback-deployed autonomous system closest to the destination node in a network routing path, recursively querying a traceback server associated with the traceback-deployed autonomous system to receive the identity of a preceding traceback-deployed autonomous system in the network routing path, and determining the network routing path based on the received identities of traceback-deployed autonomous systems. Additionally, authentication for traceback request is achieved using token delivery, wherein token is fragmented and marking of a packet is performed when a field on the packet matches at least one token fragment.

Embodiments of the invention are directed to a macromolecular chemotherapeutic. A non-limiting example of the macromolecular chemotherapeutic includes a block copolymer. The block copolymer can include a water-soluble block, a cationic block, and a linker, wherein the linker is connected to the water-soluble bock and the charged block.

Various embodiments may provide a comparator circuit arrangement. The comparator circuit arrangement may include a preamplifier having a first input configured to be coupled to a first input voltage, a second input configured to be coupled to a second input voltage, and an output configured to generate a preamplifier output signal based on the first input voltage and the second input voltage. The comparator circuit arrangement may also include a switch circuit arrangement coupled to the preamplifier, the switch circuit arrangement configured to deactivate the preamplifier upon the second input voltage exceeding the first input voltage and further configured to activate the preamplifier upon a fall of the second input voltage, and a pull-up circuit arrangement coupled to the output of the preamplifier, the pull-up circuit arrangement configured to provide a boost voltage to the preamplifier output signal for a predetermined duration upon the fall of the second input voltage.

Various embodiments may provide an optical assembly. The optical assembly may include a substrate with a first and a second grooves, and a photonic integrated circuit chip with a coupling waveguide, a first and a second grooves. The optical assembly may further include a first and a second cylindrical rods held by the respective grooves of the substrate and the photonic integrated circuit chip. A portion of the first rod and a portion of the second rod define a vertical offset between the photonic integrated circuit chip and the substrate to align the coupling waveguide with an optical fiber.

The disclosure provides anti-DENV antibodies having a cross-reactivity to ZIKV and methods of making and using the same. The anti-DENV antibodies have uses that include treating or preventing ZIKV infection.